Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TTM Capital, established in late 2020, operates from Shanghai, China, and focuses on early and growth-stage investments in the healthcare sector. The firm was founded by a team with extensive backgrounds in life sciences and healthcare, aiming to address unmet needs in the global healthcare market. TTM Capital's investment strategy is driven by a commitment to high-quality opportunities in technology-driven biopharmaceuticals, medical devices, in vitro diagnostics, and related fields.
As of now, TTM Capital manages a fund size of $130 million, with a focus on sectors such as biotech, healthcare, medical devices, and digital health. The firm has made significant strides in its short history, including notable exits like XinThera, which was acquired by Gilead Sciences for $9.6 billion within two years of its founding. TTM Capital's team comprises experienced professionals who leverage their industry connections to enhance portfolio company growth.
TTM Capital's approach combines a global perspective with a deep understanding of the healthcare landscape, allowing it to identify and support innovative companies that are poised to make a significant impact in their respective fields. The firm continues to expand its portfolio and influence within the healthcare investment community.
TTM Capital primarily invests in the biopharmaceutical sector, with a strong emphasis on oncology, immunology, and metabolic diseases. The firm seeks to create value through deep connections and collaborations within the healthcare ecosystem, focusing on segments where it has significant advantages. TTM Capital's investment strategy is characterized by a selective approach, targeting companies that address unmet global medical needs through technology-driven innovation.
The firm is open to various stages of investment, ranging from pre-seed to growth equity, allowing it to support companies at different points in their development. TTM Capital's check sizes are not publicly disclosed, but the firm is known for its active involvement in the healthcare sector, particularly in Asia and globally. The firm emphasizes long-term partnerships and strategic alliances, which are crucial for fostering innovation and growth in its portfolio companies.
TTM Capital's thesis revolves around backing healthcare and life-science companies that leverage technology to solve pressing medical challenges. This focus on innovation and collaboration positions TTM Capital as a valuable partner for founders looking to navigate the complexities of the healthcare market.
TTM Capital's portfolio includes a diverse range of companies focused on healthcare innovation:
Lily Zhang: Founding Managing Partner. Lily has a strong background in therapeutics, medical devices, and biotech, previously serving as a partner at CDH Investment and holding management roles at Johnson & Johnson and GlaxoSmithKline China Investment.
YunFei Chai: Partner. YunFei brings over a decade of experience in pharmaceutical investment, having previously served as General Manager at Langrun Investment Group, specializing in pharmaceutical incubation and M&A.
HaiDing Yang: Partner. HaiDing has over 20 years of experience in multinational financial institutions and cross-border investment/M&A transactions, with prior roles at PKI Ventures, Cathay Capital, and Credit Suisse.
Xun Ji: Investment Director. Xun has a background in biopharmaceutical investments and incubation, having previously worked at GSK and Jiuzhang Biotech.
YunZhu Liu: Finance/Operations Director. YunZhu has experience in fund investment, financial management, and post-investment management, with prior roles at Shanghai Real Estate Ventures and PwC.
Di Qiu: Legal Director. Di is a legal professional with experience in PE/VC, having worked at SoftBank China Capital and Shanghai Links Law Office.
On December 16, 2025, TTM Capital announced the first close of its RMB Fund II, securing RMB 900 million in commitments. This marks a significant milestone for the firm, indicating its ongoing fundraising and investment activities.
TTM Capital continues to expand its portfolio, focusing on innovative healthcare companies that address unmet medical needs. The firm remains active in identifying and supporting startups that align with its investment thesis.
What are TTM Capital's investment criteria?
TTM Capital primarily invests in the biopharmaceutical sector, focusing on oncology, immunology, and metabolic diseases. The firm seeks companies that address unmet global medical needs through technology-driven innovation.
How can founders pitch TTM Capital?
Founders interested in pitching TTM Capital should prepare a detailed presentation that outlines their business model, market potential, and how their solution addresses specific healthcare challenges. While specific application channels are not disclosed, establishing a connection through industry networks may be beneficial.
What makes TTM Capital different from other investors?
TTM Capital distinguishes itself through its deep connections within the healthcare ecosystem, which facilitates access to industry resources and strategic partnerships that enhance portfolio company growth.
What is TTM Capital's geographic focus?
TTM Capital has a global investment perspective, with a primary focus on Asia, particularly China. The firm also considers opportunities in the U.S. and other international markets.
What is TTM Capital's fund size and check size?
TTM Capital's fund size is $130 million, but specific check sizes for investments have not been publicly disclosed.
What kind of post-investment involvement does TTM Capital have?
TTM Capital actively engages with its portfolio companies, providing support through strategic partnerships, industry connections, and operational guidance to help drive growth and innovation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.